Current Management of Pediatric Vitiligo
Open Access
- 29 May 2015
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 17 (4) , 303-313
Abstract
Vitiligo is a common inflammatory disorder with worldwide prevalence of 0.4–2 % of the population, with half of cases beginning in childhood. The management of childhood vitiligo should be tailored to avoid negative effects on the overall growth and psychological development of the patient. Therapy of vitiligo in childhood is chosen based on the location of the lesions, lesion age, and extent of lesions in the context of the child’s age and the developmental status of the child. There are four age categories in childhood vitiligo: [ 1 ] infantile and toddler (rare) (ages 0–3 years), [ 2 ] ages 4–8 years, [ 3 ] ages 9–12 years, and [ 4 ] 13+ years of age, based on developmental stage, psychological maturation, and ability to comply or participate in therapy. These categories are also differentiated psychologically by susceptibility to bullying, self-image development, and personal concern with lesion appearance, which increases with time. Intervention is advisable in cases with facial and leg involvement due to prominence of lesions and cosmetic defect. Medical interventions are largely the usage of topical therapies including corticosteroids and calcineurin inhibitors, some vitamin therapy (oral and topical vitamin D), and judicious introduction of phototherapy sources based on age and severity. Screening and appropriate subspecialist referral for co-morbidities (e.g., thyroid disease, celiac disease, psychological distress, and vitamin D deficiency) may enhance overall health. Cosmesis and camouflage are generally safe in childhood and have been noted to improve overall quality of life in this grouping. Genetic transmission of vitiligo is minimal at 5–6 % in first-degree relatives. This article reviews the therapeutics of pediatric vitiligo from the perspective of developmental stages and response to therapy.Keywords
This publication has 84 references indexed in Scilit:
- Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily PracticeAmerican Journal of Clinical Dermatology, 2013
- The effectiveness of early treatment in segmental vitiligo: retrospective study according to disease durationPhotodermatology, Photoimmunology & Photomedicine, 2013
- A review of monochromatic excimer light in vitiligoBritish Journal of Dermatology, 2012
- Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus ConferencePigment Cell & Melanoma Research, 2012
- Original article title: "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial"BMC Dermatology, 2011
- Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trialBMC Complementary and Alternative Medicine, 2011
- Shared Genetic Relationships Underlying Generalized Vitiligo and Autoimmune Thyroid DiseaseThyroid®, 2010
- Therapeutic interventions for vitiligoJournal of the American Academy of Dermatology, 2008
- Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligoJournal of the American Academy of Dermatology, 2005
- Childhood vitiligoJournal of the American Academy of Dermatology, 1987